Nihon Kagaku Sangyo Co., Ltd.
Regarding Personnel Changes
Hiroki Sumitani will assume the position of Representative Director and President effective June 26, 2026, and Osamu Matsuo is scheduled to assume the role of Director and Executive Managing Officer, Head of Pharmaceutical Business Headquarters.
Key Figures
- Scheduled Appointment Date for Representative Director and President: 2026-06-26
- Scheduled Appointment Date for New Director Candidate: 2026-06-26
- Name of Representative Director and President: Hiroki Sumitani
AI要約
Summary of Executive Personnel Changes
Nihon Kagaku Sangyo Co., Ltd. resolved at the Board of Directors meeting held on April 28, 2026, the director personnel changes effective June 26, 2026. Mr. Hiroki Sumitani will assume the position of Representative Director and President, changing from his current role as Representative Director, President, and head of Pharmaceutical Business Headquarters. Additionally, Mr. Osamu Matsuo is scheduled to become Director and Executive Managing Officer, Head of Pharmaceutical Business Headquarters. These changes will be formally approved at the Annual General Meeting of Shareholders scheduled for June 26 of the same year.
Impact on Shareholders and Corporate Strategy
This executive change aims to refresh the management structure and is expected to strengthen the governance of the pharmaceutical business division. The change in Representative Director and President anticipates further operational efficiency and business expansion, although the precise impact on financial performance is currently unclear. Formal approval at the shareholder meeting is required, making subsequent developments noteworthy.
Nihon Kagaku Sangyo Co., Ltd.
Company overview · Stock price · Financial data · All IR
